-$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter

Wall Street brokerages expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to report earnings per share of ($0.25) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings, with estimates ranging from ($0.33) to ($0.17). Sunesis Pharmaceuticals reported earnings per share of ($0.44) in the same quarter last year, which would indicate a positive year over year growth rate of 43.2%. The business is expected to issue its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.66) to ($1.48). For the next financial year, analysts anticipate that the company will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same period last year, the business posted ($0.62) EPS.

Several equities research analysts have recently weighed in on SNSS shares. Zacks Investment Research downgraded shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. UBS Group started coverage on shares of Sunesis Pharmaceuticals in a report on Monday, November 20th. They set an “outperform” rating for the company. Oppenheimer started coverage on shares of Sunesis Pharmaceuticals in a report on Tuesday, November 21st. They set an “outperform” rating and a $7.00 price target for the company. Finally, Wells Fargo & Co cut shares of Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $2.70 to $2.00 in a report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Sunesis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $3.75.

In other news, major shareholder Mpm Oncology Impact Management purchased 81,500 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $2.77 per share, with a total value of $225,755.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.21% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Balyasny Asset Management LLC purchased a new position in Sunesis Pharmaceuticals during the second quarter worth about $5,400,000. Vanguard Group Inc. increased its holdings in Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Sunesis Pharmaceuticals by 127.6% in the third quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 53,396 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in Sunesis Pharmaceuticals in the second quarter valued at about $208,000. 38.21% of the stock is owned by hedge funds and other institutional investors.

Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $4.61 on Monday. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.72. The firm has a market cap of $153.77, a PE ratio of -2.63 and a beta of 1.53. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.

COPYRIGHT VIOLATION WARNING: “-$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/29/0-25-eps-expected-for-sunesis-pharmaceuticals-inc-snss-this-quarter.html.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply